GSK plc (LON:GSK) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is GBX 1,842.50 ($23.47).

A number of equities analysts have weighed in on GSK shares. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,850 ($23.56) target price on shares of GSK in a report on Tuesday, September 3rd. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,820 ($23.18) price target on shares of GSK in a report on Tuesday, September 10th.

GSK Stock Performance

Shares of GSK opened at GBX 1,336.33 ($17.02) on Monday. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a 50-day moving average of GBX 1,437.76 and a 200-day moving average of GBX 1,552.20. The company has a market cap of £54.52 billion, a PE ratio of 1,182.59, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a one year low of GBX 1,282.50 ($16.34) and a one year high of GBX 1,823.50 ($23.23).

GSK Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a yield of 1.03%. GSK’s payout ratio is currently 5,309.73%.

Insider Activity at GSK

In related news, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average cost of GBX 2,051 ($26.12) per share, for a total transaction of £9,147.46 ($11,651.33). Also, insider Jonathan Symonds acquired 7,150 shares of the stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($17.76) per share, for a total transaction of £99,671 ($126,953.25). Insiders bought 7,604 shares of company stock worth $10,893,038 in the last ninety days. 1.61% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.